Company Analysis

Oramed Pharmaceuticals Inc. (ORMP)

Nasdaq: ORMP · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2002
Grade5.3
◀ Past 6.0● Present 6.0▶ Future 4.3

Who runs Oramed Pharmaceuticals Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kidron Nadav
President and CEO. First filing Mar 2006, latest Sep 25, 2026, 6 filings in all.
Officers reporting now
4
of 8 people with a filing in the last fifteen months
Directors reporting now
4
24 people on the record since 2006
Officerssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Gabay AvrahamChief Financial OfficerJun 2019Oct 2, 20262 · $400,000
Hexter JoshuaCOO & CBOApr 2013Oct 2, 20262 · $700,000
Kidron NadavPresident and CEOMar 2006Sep 25, 2026none
Kidron MiriamChief Scientific OfficerAug 2007Sep 25, 2026none
Directorssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Mayer AriedirectorDec 2019Jan 5, 2026none
Reznick YehudadirectorApr 2024Jan 5, 2026none
Shapiro BenjamindirectorMay 2023Jan 5, 2026none
Aghion DanieldirectorJan 2024Jan 2, 2026none
Earlier names on the record16, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ORMP · research, not advice